GlassScriptPhysician profile
Alex Jonathan Dickert
NPI 1427342245
$2,463.10
in general payments reported to CMS, 2019-2025
26 companies · $15.80 in 2025
The $15.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $521 · 2021: $392 · 2022: $181 · 2023: $253 · 2024: $137 · 2025: $15.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.05 | 2019-2023 | Jardiance |
| Amgen INC. | $340.62 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $328.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $249.79 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Edwards Lifesciences Corporation | $183.40 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $174.00 | 2019-2021 | |
| Novo Nordisk INC | $172.54 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $148.09 | 2019-2024 | |
| Lilly USA, LLC | $93.08 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $57.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.67 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $46.16 | 2022 | |
| Merck Sharp & Dohme LLC | $43.56 | 2019-2020 | |
| Abbvie INC. | $28.76 | 2021 | |
| Astellas Pharma US INC | $21.28 | 2023 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $19.17 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.94 | 2019 | |
| Echosens North America, INC. | $17.73 | 2024 | Fibroscan |
| Endogastric Solutions, INC | $16.87 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.77 | 2019 | |
| Circassia INC. | $13.35 | 2019 | |
| Roche Diagnostics Corporation | $11.83 | 2019 | |
| Eisai INC. | $11.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.56 | 2021 | |
| Genentech USA, INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Dickert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.